IPX 159

Drug Profile

IPX 159

Alternative Names: IPX-159

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator Impax Pharmaceuticals
  • Class Sleep disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Restless legs syndrome

Most Recent Events

  • 28 Feb 2013 Discontinued - Phase-II for Restless legs syndrome in USA (PO)
  • 28 Feb 2013 Discontinued - Phase-II for Restless legs syndrome in Australia (PO)
  • 01 Feb 2013 Impax Pharmaceuticals completes a phase IIb trial in Restless legs syndrome in USA (NCT01521663)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top